v3.26.1
Equity Incentive Plan - Summary of Stock Based Compensation Expense Regarding its Employees and Nonemployees (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Research and Development Expense $ 25,644 $ 39,272 $ 59,599 $ 80,737
General and Administrative Expense 9,293 6,626 28,149 16,441
AnaptysBio' s 2017 Plan        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation expense 1,472 15,402 12,975 7,656
First Tracks Equity Plan        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation expense 6,847      
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | AnaptysBio' s 2017 Plan        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation expense 738 6,344 7,695 3,036
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | First Tracks Equity Plan        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation expense 3,251      
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | AnaptysBio' s 2017 Plan        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation expense 734 $ 9,058 $ 5,280 $ 4,620
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | First Tracks Equity Plan        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation expense $ 3,596